---
title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Incidence"
description: "Formulary evidence on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis: Incidence. Topics: United States, 2023: reported acute hepatitis B cases, estimated infections, and rate; United States, 2023: acute hepatitis B by age, sex, race and ethnicity, and reported risk; United States, 2023: newly reported chronic hepatitis B cases and rate; United States, 2020 model: new chronic infections imported through immigration; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description/incidence"
published: "2026-10-21T22:39:04-04:00"
modified: "2026-10-22T19:07:03-04:00"
---
# Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Incidence
## 2.2.1.2.1 Incidence of Chronic hepatitis B virus infection in adults without cirrhosis
### United States, 2023: reported acute hepatitis B cases, estimated infections, and rate
> “During 2023, a total of 2,214 acute hepatitis B cases were reported to CDC by 47 states and the District of Columbia, corresponding to an estimated 14,400 acute infections (95% CI: 8,200–35,200) after adjusting for case underascertainment and underreporting”
> “The reported case count corresponds to a rate of 0.7 cases per 100,000 population. Following a decade of stable rates from 2011–2019, a decrease was observed from 2019–2020, and rates have remained relatively stable through 2023.”
> “A total of 779 patients, or 64% of 1,215 cases for which hospitalization information was available, were hospitalized due to acute hepatitis B during 2023.”
Source: [CDC Viral Hepatitis Surveillance Report national profile (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/about/national-profile.html)
### United States, 2023: acute hepatitis B by age, sex, race and ethnicity, and reported risk
> “The highest rate of reported acute hepatitis B cases was among persons aged 40–49 years (1.4 cases per 100,000 population), followed by persons aged 50–59 years (1.2 cases per 100,000 population).”
> “Most acute hepatitis B cases were reported among males (62%). In 2023, the rate of reported cases was 1.7 times as high among males compared to females.”
> “The rate of reported acute hepatitis B cases among non-Hispanic Black persons was 1.9 times as high compared to non-Hispanic White persons.”
> “During 2023, the most commonly reported risks (based on proportion of cases with available data reporting the risk) included injection drug use (19% of the 963 cases with information available), having multiple sexual partners (20% of the 528 cases with information available), and male-to-male sexual contact (21% of the 256 male cases with information available).”
Source: [CDC Viral Hepatitis Surveillance Report national profile (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/about/national-profile.html)
### United States, 2023: newly reported chronic hepatitis B cases and rate
> “During 2023, a total of 17,650 newly reported cases of chronic hepatitis B were reported to CDC by 44 states and the District of Columbia, corresponding to a rate of 6.1 cases per 100,000 population. Approximately 89% of newly reported cases of chronic hepatitis B were among persons aged 30 years and older, and most were reported among males (57%).”
> “The rate of newly reported chronic hepatitis B cases was highest among non-Hispanic A/PI persons (18.9 cases per 100,000 population), which was 9.9 times the rate among non-Hispanic White persons (1.9 cases per 100,000 population).”
Source: [CDC Viral Hepatitis Surveillance Report national profile (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/about/national-profile.html)
> “The rate of newly reported chronic hepatitis B cases was highest among persons aged 30–39 and 40–49; these two age groups combined accounted for 46% of all newly reported chronic hepatitis B cases.”
> “Although the rate of reported acute hepatitis B cases was the lowest among non-Hispanic A/PI persons, the rate of newly reported chronic hepatitis B cases was highest among this group.”
Source: [CDC Viral Hepatitis Surveillance Report (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/hepatitis-b/index.html)
### United States, 2020 model: new chronic infections imported through immigration
> “In 2020, it was estimated that 96% (35,000 imported out of 36,400 new chronic cases) of all chronic HBV incident cases (new chronic infections) were among immigrants entering the country, imported chronic cases, with the rest caused by ongoing transmission occurring within the US.”
Source: [Razavi-Shearer et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10239007/)
### Global, 2024: new hepatitis B virus infections
> “Globally, the number of people newly infected with HBV in 2024 was 0.9 million (95% UI: 0.7–1.2 million); this was a decline of 32% from 2015. The WHO African Region accounted for 68% of new infections in 2024.”
Source: [WHO Global hepatitis report (2026)](https://iris.who.int/server/api/core/bitstreams/6f6caedc-37a0-49ee-a02a-df9c3b78ff42/content)
> “WHO estimates that 240 million people were living with chronic hepatitis B infection in 2024, with 0.9 million new infections each year.”
Source: [WHO hepatitis B fact sheet (2026)](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)
## Related pages
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md)
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)